Tenofovir: What have over 1 million years of patient experience taught us?

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1285-1293

  Pozniak, A ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMIDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHEMICAL STRUCTURE; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DAMAGE; LIPOATROPHY; MONOTHERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS;

EID: 47149106032     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01817.x     Document Type: Review

References (65)

1. Gilead Sciences, Inc. Gilead Sciences. Data on File. Gilead Sciences, Inc., 2007.
2. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003 16 : 569 96.
3. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004 37 (Suppl. 1 S2 12.
4. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998 42 : 612 7.
5. Tsai CC, Follis KE, Sabo A et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995 270 : 1197 9.
6. Barditch-Crovo P, Deeks SG, Collier A et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001 45 : 2733 9.
7. Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995 333 : 1662 9.
8. McColl DJ, Miller MD. The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1. J Antimicrob Chemother 2003 51 : 219 23.
9. Srinivas RV, Fridland A. Antiviral activities of 9-R-2- phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998 42 : 1484 7.
10. Wainberg MA, Miller MD, Quan Y et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999 4 : 87 94.
11. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999 179 : 92 100.
12. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002 16 : 1257 63.
13. Squires K, Pozniak AL, Pierone G Jr et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003 139 : 313 20.
14. Margot NA, Isaacson E, McGowan I et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002 16 : 1227 35.
15. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004 292 : 191 201.
16. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006 7 : 487 503.
17. Cassetti I, Madruga JVR, Suleiman JMAH et al. The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naïve patients. Presented at the 8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow : Poster 152.
18. Madruga JVR, Cassetti I, Suleiman JMAH et al. Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) resulted in continued virologic suppression and improvement in lipoatrophy through 2 years in HIV-infected patients. Presented at the 8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow : Poster 29.
19. Madruga JV, Cassetti I, Koenig E et al. Six year safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-naive patients. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney : WEPEB030.
20. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006 20 : 2043 50.
21. Moyle G, Fisher M, SWEET Study Group. A randomized comparison of continued zidovudine plus lamivudine BID (AZT/3TC) versus switching to tenofovir DF plus emtricitabine (FTC/TDF) each plus efavirenz (EFV) in stable HIV infected persons: 48 week study - results of a planned 24 week analysis. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney : WEPEB028.
22. Moyle G, Fisher M, SWEET Study Group. Factors associated with low limb fat in a cohort of zidovudine-treated subjects. Presented at the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney : Poster P12.
23. Fisher M, Moyle G, Ebrahimi R, SWEET Study Group. Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) maintains viral suppression, prevents and reverses limb fat loss, and improves biochemical parameters: results of a 48 week randomised study. Presented at the 11th European AIDS Conference, 24-27 October 2007, Madrid : PS5/7.
24. Martinez E, Arranz JA, Podzamczer D et al. Efficacy and safety of NRTIs switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO study. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney : WESS102.
25. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006 354 : 251 60.
26. Pozniak AL, Gallant JE, DeJesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006 43 : 535 40.
27. Arribas JR, Pozniak AL, Gallant JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008 47 : 74 8.
28. Rousseau FS, Wakeford C, Mommeja-Marin H et al. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis 2003 188 : 1652 8.
29. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr 2003 34 : 243 5.
30. Moyle GJ. The role of zidovudine in development of lipoatrophy. AIDS Read 2005 15 : 591 600.
31. Staszewski S, Pozniak AL, Gallant J et al. Renal safety profile of Tenofovir DF (TDF)-containing compared to non-TDF-containing regimens in antiretroviral-naive patients with mild renal impairment or hypertension and/or diabetes mellitus. Presented at the 8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow.
32. Estrada V, Ena J, Domingo P et al. Renal safety of tenofovir DF in HIV treatment-experienced patients with adverse events related to NRTI use. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 30 October-2 November 2004, Washington, DC : Poster H-169.
33. Fux CA, Simcock M, Wolbers M et al. Tenofovir treatment is associated with a decrease in calculated glomerular filtration rates in a large observational cohort. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA : Poster 834.
34. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 2004 37 : 1489 95.
35. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005 40 : 1194 8.
36. Nelson MR, Katlama C, Montaner JS et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007 21 : 1273 81.
37. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002 324 : 342 4.
38. Creput C, Gonzalez-Canali G, Hill G et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003 17 : 935 7.
39. Harris M, Alunardo M, Yip B. Nephrotoxicity of tenofovir DF. Can J Infect Dis 2003 14 : 25A.
40. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003 36 : 1070 3.
41. Reynes J, Peyriere H, Merle de Boever C, Le Moing V. Renal tubular injury and severe hypophosphotemia (Fanconi syndrome) associated with tenofovir therapy. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003, Boston, MA.
42. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002 40 : 1331 3.
43. Jones R, Scott C, Nelson M, Levy J. Renal complications in HIV. Int J Clin Pract 2007 61 : 991 8.
44. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005 40 : 1559 85.
45. Fernandez-Rivera J, Garcia R, Lozano F et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003 4 : 337 46.
46. Moore AL, Vashisht A, Sabin CA et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001 15 : 1731 3.
47. Tebas P, Powderly WG, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000 14 : F63 7.
48. Amiel C, Ostertag A, Slama L et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004 19 : 402 9.
49. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003 17 : 1917 23.
50. Landonio S, Quirino T, Bonfanti P et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother 2004 58 : 505 8.
51. Tebas P, Umbleja T, Dube M et al. Initiation of ART is associated with bone loss independent of the specific ART regimen. The results of ACTG A5005s. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA : P837.
52. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005 6 : 341 6.
53. Bonora S, Gonzalez de Requena D, Chiesa E et al. Transplacental passage of tenofovir (TDF) and other antiretrovirals (ARVs) at delivery. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA : Poster 738a.
54. Burchett SK, Best B, Mirochnick M et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, 25-28 February 2007, Los Angeles, CA : P738b.
55. Martelli S, Long K, Berdot S. Placental transfer of tenofovir in HIV-infected women treated with TDF and protease inhibitors containing regimen. Presented at the 11th European AIDS Conference, 24-27 October 2007, Madrid : Poster P14.7/01.
56. Information available at http://www.clinicaltrials.gov/ (accessed November 2007).
57. Smith K, Weinberg W, DeJesus E et al. Once-daily ritonavir (100 mg) boosting of fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naive HIV-infected patients: 48-week safety/efficacy results from COL103952 (ALERT). Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney : WEPEB023.
58. Raffi F, Ward D, Ruxrungtham K et al. Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD as initial therapy in HIV-1 infected patients: the Gemini study. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney : WEPEB027.
59. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004 36 : 808 16.
60. Heathcote E, Gane E, DeMan R et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, 2-6 November 2007, Boston, MA : LB6.
61. Marcellin P, Buti M, Krastev Z et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases, 2-6 November 2007, Boston, MA : LB2.
62. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005 19 : 593 601.
63. Mauss S. Long term suppression of HBV by tenofovir in HIV/HBV-coinfected patients. Presented at the Third International Workshop on HIV and Hepatitis Coinfection, 7-9 June 2007, Paris : Abstract 38.
64. Tan L. Long-term treatment with tenofovir in an open label study of individuals co-infected with HIV and hepatitis B. Presented at the Third International Workshop on HIV and Hepatitis Coinfection, 7-9 June 2007, Paris : Abstract 41.
65. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006 57 : 815 8.